AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24568907
Drug: Huangqi injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huangqi injection (0.5 mL/kg·d for 35 days)
Trial: 22777368
Drug: Uterosacral vault
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uterosacral vault suspension with perioperative pelvic floor muscle training
Trial: 22777368
Drug: Uterosacral vault
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uterosacral vault suspension without perioperative pelvic floor muscle training
Trial: 16054381
Drug: Protamine administered
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protamine administered 5 min after cardiopulmonary bypass
Trial: 16054381
Drug: Protamine administered
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protamine administered 35 min after cardiopulmonary bypass
Trial: 10418923
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated human-bovine reassortant rotavirus vaccine (D x UK) - single oral dose (10^5.3 pfu)
Trial: 10418923
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated human-bovine reassortant rotavirus vaccine (DS-1 x UK) - single oral dose (10^5.8 pfu)
Trial: 10418923
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated human-bovine reassortant rotavirus vaccine (P x UK) - single oral dose (10^5.8 pfu)
Trial: 10418923
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated human-bovine reassortant rotavirus vaccine (ST3 x UK) - single oral dose (10^5.8 pfu)
Trial: 10418923
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated human-bovine reassortant rotavirus vaccine (D x UK) - two doses
Trial: 7908246
Drug: Inhaled formoterol
RxNorm normalized name: formoterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled formoterol (12 micrograms)
Trial: 138664
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate containing 60 mg elemental iron twice daily
Trial: 138664
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5 mg twice daily
Trial: 138664
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of iron and folic acid
Trial: 24392555
Drug: Subconjunctival bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subconjunctival bevacizumab (2.5 mg/0.1 ml)
Trial: 24392555
Drug: Topical bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Topical bevacizumab (2.5%, 25 mg/ml)
Trial: 24392555
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection (Control Group B)
Trial: 11033396
Drug: Direct argon-green
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct argon-green laser photocoagulation for CNV treatment
Trial: 9183445
Drug: Classical biological
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical biological explorations
Trial: 8331618
Drug: Low-dose insulin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose insulin infusion (0.25 mU/kg/min)
Trial: 8331618
Drug: High-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose insulin infusion (1.0 mU/kg/min)
Trial: 8331618
Drug: Basal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal and insulin infusion periods
Trial: 20880171
Drug: Lafutidine 10
RxNorm normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lafutidine 10 mg administered twice daily for 14 days
Trial: 20880171
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered twice daily for 14 days
Trial: 18248495
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (standard therapy)
Trial: 17176334
Drug: Higher transfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher transfusion threshold (10 g per dL)
Trial: 17176334
Drug: Lower transfusion
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower transfusion threshold (7 g per dL)
Trial: 10854006
Drug: Lacidipine (4‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine (4‐6 mg od)
Trial: 10854006
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) (25‐50 mg od)
Trial: 29678523
Drug: Adipose tissue-derived
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adipose tissue-derived mesenchymal stem cell (ASC) therapy
Trial: 27326859
Drug: Azithromycin-Chloroquine (AZCQ;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin-Chloroquine (AZCQ; 250 mg AZ/155 mg CQ base)
Trial: 27326859
Drug: Sulfadoxine-Pyrimethamine (SP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-Pyrimethamine (SP; 1,500/75 mg SP QD for 1 day)
Trial: 18588481
Drug: IC51 (inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IC51 (inactivated Japanese encephalitis vaccine)
Trial: 11092282
Drug: Ultralente insulin
RxNorm normalized name: ultralente insulin, beef
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultralente insulin therapy
Trial: 8340194
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg bid for 5-14 days
Trial: 8340194
Drug: Cefadroxil 500
RxNorm normalized name: cefadroxil 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil 500 mg bid for 5-14 days
Trial: 8340194
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg qid for ≤ 14 days
Trial: 8340194
Drug: Erythromycin 250
RxNorm normalized name: erythromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 250 mg qid for ≤ 14 days
Trial: 21194827
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefenamic acid (500 mg)
Trial: 18362485
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (n = 29)
Trial: 12911202
Drug: Macintosh laryngoscope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macintosh laryngoscope (group L)
Trial: 10571611
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of pantoprazole (2 x 40 mg, Group 2PCA)
Trial: 10571611
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of pantoprazole (40 mg, Group 1PCA)
Trial: 10571611
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens (double and single dose of pantoprazole)
Trial: 1925193
Drug: Fixed triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed triple combination (0.05 mg reserpine, 2.5 mg clopamide, 0.4 mg dihydroergocristine)
Trial: 1925193
Drug: Fixed double
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed double combination (0.05 mg reserpine, 2.5 mg clopamide)
Trial: 1925193
Drug: Fixed triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed triple combination
Trial: 1925193
Drug: Fixed double
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed double combination
Trial: 28027794
Drug: Intraperitoneal vancomycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal vancomycin, 1g, every 5 days plus oral moxifloxacin, 400mg, every day
Trial: 25863661
Drug: High-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose recombinant human erythropoietin (rhEpo) 3000 U/kg body weight
Trial: 25863661
Drug: High-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose recombinant human erythropoietin (rhEpo)
Trial: 21335616
Drug: PONI (modular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PONI (modular protocol for on-site, nurse-administered intervention)
Trial: 11293559
Drug: 100-mg sumatriptan
RxNorm normalized name: sumatriptan 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-mg sumatriptan tablets
Trial: 11293559
Drug: 50-mg sumatriptan
RxNorm normalized name: sumatriptan 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-mg sumatriptan tablets
Trial: 8083076
Drug: r‐HuEPO (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐HuEPO (200 U/kg/day) and ferrous sulfate 5‐10 days prior to initiation of external beam radiation therapy
Trial: 2754150
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose of 4.5% saline via higher output nebulizer
Trial: 31005385
Drug: Levetiracetam (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (40 mg/kg over 5 min)
Trial: 31005385
Drug: Phenytoin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin (20 mg/kg over at least 20 min)
Trial: 25811584
Drug: 50% inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% inhaled oxygen
Trial: 23789452
Drug: hilifox‐750 (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hilifox‐750 (750 mg daily for 5 days)
Trial: 23789452
Drug: amoxiclav (875/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amoxiclav (875/125 mg twice daily for 10 days)
Trial: 20696676
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with cisplatin-docetaxel (D 75 mg/m² on day 1 and C 40 mg/m² on days 1 and 2) followed by concurrent chemoradiotherapy (66 Gy with weekly D 20 mg/m² and C 20 mg/m²)
Trial: 20696676
Drug: Consolidation chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation chemotherapy with cisplatin-docetaxel (D 75 mg/m² on day 1 and C 40 mg/m² on days 1 and 2) followed by concurrent chemoradiotherapy (66 Gy with weekly D 20 mg/m² and C 20 mg/m²)
Trial: 12634224
Drug: CsA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA plus MTX combination therapy
Trial: 9367069
Drug: Oral retinol
RxNorm normalized name: retinol
DrugBank: Vitamin A (DB00162)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral retinol (25,000 IU) daily for up to 5 years
Trial: 3866866
Drug: Weekly mouthrinsing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly mouthrinsing with a 0.2 percent NaF solution
Trial: 3866866
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (semiannual fluoride varnish treatments)
Trial: 25219106
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy (OIT) with wheat, up-dosing phase until 100 g tolerated, followed by 6-month maintenance phase
Trial: 25219106
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy (OIT) with wheat
Trial: 22872467
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg E(2)
Trial: 20968271
Drug: Quercetin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin supplementation (1 g/d for 6 weeks)
Trial: 18303020
Drug: sifuvirtide (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sifuvirtide (5, 10, 20, 30, and 40 mg) by subcutaneous injection once daily
Trial: 12747278
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg prednisone daily
Trial: 25382826
Drug: Prodrug (LY2140023)
RxNorm normalized name: Troxacitabine nucleotide prodrug miv-818
DrugBank: Fostroxacitabine bralpamide (DB18090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prodrug (LY2140023) 80 mg oral
Trial: 25382826
Drug: Prodrug (LY2140023)
RxNorm normalized name: Troxacitabine nucleotide prodrug miv-818
DrugBank: Fostroxacitabine bralpamide (DB18090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prodrug (LY2140023) 80 mg oral and 100 μg i.v.
Trial: 25382826
Drug: Active moiety
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active moiety (LY404039) 100 μg i.v.
Trial: 24342198
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (HFOV, PS, iNO)
Trial: 24342198
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (HFOV, iNO)
Trial: 11499744
Drug: L-arginine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (15 g daily)
Trial: 7528908
Drug: Interferon treatment
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon treatment in 17 children
Trial: 28258526
Drug: Medication advertisement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication advertisement
Trial: 17009253
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of sCT
Trial: 17009253
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of sCT
Trial: 3114548
Drug: Bupranolol 100
RxNorm normalized name: bupranolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupranolol 100 mg
Trial: 24029546
Drug: Oral laquinimod
RxNorm normalized name: laquinimod
DrugBank: Laquinimod (DB06685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral laquinimod (0.6 mg)
Trial: 20503023
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon plus ribavirin (800-1200 mg/d)
Trial: 10882164
Drug: Tropisetron monotherapy
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron monotherapy
Trial: 10882164
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dexamethasone and tropisetron
Trial: 10882164
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose metoclopramide plus dexamethasone
Trial: 31784365
Drug: Leukocyte-rich platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocyte-rich platelet-rich plasma (PRP) injection
Trial: 30528317
Drug: Mupirocin ointment
RxNorm normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mupirocin ointment (2%) dressings
Trial: 25510856
Drug: Clarithromycin (CYP3A4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (CYP3A4 inhibitor)
Trial: 25510856
Drug: Clarithromycin +
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin + Paroxetine (CYP3A4 + CYP2D6 inhibitors)
Trial: 25510856
Drug: O‐desmethylvenlafaxine <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O‐desmethylvenlafaxine < 4 and venlafaxine + O‐desmethylvenlafaxine > 400 ng/ml
Trial: 19147401
Drug: OSAS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSAS treatment (CPAP and MAD)
Trial: 16903598
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Yueyueshu Powder, twice a day, 10 g each time for 3 menstrual cycles
Trial: 9251274
Drug: ACTHIB vaccine
RxNorm normalized name: ActHIB vaccine 0.5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTHIB vaccine given with primary immunization (age group 6 to 8 weeks) in 50 babies
Trial: 9251274
Drug: ACTHIB vaccine
RxNorm normalized name: ActHIB vaccine 0.5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTHIB vaccine
Trial: 8104070
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (HD-CY; 7 g/m2) alone
Trial: 8104070
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (HD-CY; 7 g/m2) with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF; 5 micrograms/kg/day iv after HD-CY)
Trial: 31971832
Drug: Interdisciplinary Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interdisciplinary Therapy (IT) (n = 19)
Trial: 23014796
Drug: CON (rest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CON (rest without treatment)
Trial: 19363237
Drug: Sclerovit (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sclerovit (1 capsule)
Trial: 19363237
Drug: Sclerovit (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sclerovit (2 capsules)
Trial: 10965289
Drug: Fluoxetine and
RxNorm normalized name: fluoxetine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine and behavioral treatment
Trial: 8857862
Drug: Topical 60%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 60% DMSO applied every 4 hours for 10 days after operation
Trial: 1536829
Drug: Two Gabor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two Gabor patches with different spatial frequencies identified in parallel when occupying the same spatial position.
Trial: 1536829
Drug: Two Gabor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two Gabor patches with the same spatial frequency identified in parallel even when separated by 8 degrees.
Trial: 1536829
Drug: Two Gabor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two Gabor patches with different spatial frequencies separated by 4 degrees or more.
Trial: 6369520
Drug: Single-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose group (500 mg of tinidazole intravenously preoperatively)
Trial: 6369520
Drug: 3-day group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day group (500 mg of tinidazole intravenously preoperatively + 3-day tinidazole treatment)
Trial: 28525636
Drug: Movement group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Movement group (unimanual pattern of five sequential keystrokes)
Trial: 22659072
Drug: CBT4BN (Internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT4BN (Internet-based cognitive-behavioral therapy)
Trial: 22659072
Drug: CBTF2F (traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBTF2F (traditional face-to-face cognitive-behavioral therapy)
Trial: 18838638
Drug: Medical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical management plus naltrexone therapy
Trial: 18838638
Drug: Medical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical management plus combined naltrexone and acamprosate therapy
Trial: 11859850
Drug: Second generation
RxNorm normalized name: Second generation cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second generation oral contraceptive (30 microg ethinylestradiol/150 microg levonorgestrel)
Trial: 11859850
Drug: Third generation
RxNorm normalized name: Third generation cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third generation oral contraceptive (30 microg ethinylestradiol/150 microg desogestrel)
Trial: 2938985
Drug: Desogestrel-containing preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desogestrel-containing preparations
Trial: 11859850
Drug: Progestagen-only pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestagen-only pills (150 microg desogestrel)
Trial: 23929692
Drug: Error Augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Error Augmentation (EA) training
Trial: 21817123
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with inert metal disks, same protocol as SMS
Trial: 17161670
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lafutidine b.d.
Trial: 15142209
Drug: SRP+500 mg
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP+500 mg of systemic tetracycline twice/day for 14 days
Trial: 10700052
Drug: Verapamil 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 5 mg
Trial: 17126782
Drug: Lidocaine 10
RxNorm normalized name: lidocaine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 10 mg
Trial: 9575643
Drug: Milgamma tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milgamma tablets (50 mg benfothiamine and 0.25 mg cyancobalamine)